Log In
BCIQ
Print this Print this
 

MVA-BN Filo

  Manage Alerts
Collapse Summary General Information
Company Bavarian Nordic A/S
DescriptionModified vaccinia Ankara (MVA) multivalent vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentPhase III
Standard IndicationEbola
Indication DetailsVaccinate against Ebola virus infection; Vaccinate against Ebola Zaire and Ebola Sudan viruses; Vaccinate against Ebola Zaire, Ebola Sudan and Marburg viruses
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$25.0M

$20.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/22/2014

Undisclosed

$25.0M

$20.0M

Get a free BioCentury trial today